A Multi-center, Open Label, Extension Study of RO5045337 (MDM2 Antagonist) Administered Orally in Patients Treated With RO5045337 on Previous Roche-sponsored Phase 1 Cancer Studies.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Long-term safety: incidence of adverse events
Approximately 24 months
United States: Food and Drug Administration
|Fountain Valley, California 92708|
|Austin, Texas 78705|
|Baltimore, Maryland 21287|